- ASCO® 2024
- 2024 Post ASH Highlights
- Yale Cancer Answers
- ASH CME Series
- Smilow Shares with Primary Care
- Grand Rounds
- Head and Neck
- Gynecologic
- Benign Hematology
- Breast
- GI
- Lung
- GU
- Hematologic Oncology
- Sarcoma
- Brain
- Cancer Screening
- DEI (Diversity, Equity and Inclusion)
- 2021 ASH Highlights
- General Events
- Events

Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
10 seconds
Playback speed
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Review of Ongoing Trial on Olaparib With or Without Atezolizumab in Patients with HER2- BRCAmt Breast Cancer - From Bench to Bedside & Back
By
Yale Cancer Center
FEATURING
Patricia LoRusso
By
Yale Cancer Center
FEATURING
Patricia LoRusso
24 views
August 30, 2019
Comments 0
Login to view comments.
Click here to Login
Breast